Leerink Partners Remains a Buy on Innate Pharma (IPHA)

By Carrie Williams

In a report released today, Daina Graybosch from Leerink Partners maintained a Buy rating on Innate Pharma (IPHAResearch Report), with a price target of $9.00. The company’s shares closed last Thursday at $5.75.

According to TipRanks.com, Graybosch is a 3-star analyst with an average return of 7.3% and a 36.2% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Bolt Biotherapeutics, and Genocea Biosciences.

Currently, the analyst consensus on Innate Pharma is a Strong Buy with an average price target of $8.79, a 61.0% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.90 and a one-year low of $3.02. Currently, Innate Pharma has an average volume of 1.17M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. The company’s revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.